Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine vs bendamustine + GA101 in rituximab-refractory indolent non-Hodgkin's lymphoma
2009-015504-25Phase 3Completed
- Sponsor
- Genentech
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Genentech. Primary endpoints: Progression-free survival (IRF-assessed) and Progression-free survival (investigator-assessed). Started Apr 2010; status: completed.
02
Drugs
obinutuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2009-015504-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015504-25.